In this study, we ®rst describe expression of the paired domain transcription factor PAX2 in the normal and cancerous human breast, then demonstrate in a murine model a novel function for PAX2 in the regulation of progesterone stimulation of secondary ductal growth. In human mammary tissue, PAX2 expression was coincident with sub-populations of mammary ductal cells, some of which possessed an undierentiated histiotype, and was also found in 450% of the human breast tumors surveyed (n=38). In the mouse, mammary parenchyma with a targeted deletion of PAX2 developed normal ductal systems when grafted into wild-type host mammary fat pads, but failed to undergo higher order side-branching and lobular development in response to progesterone. A previously unsuspected PAX2/WT1 (Wilms' tumor suppressor gene) regulatory axis in the mammary gland was also indicated. Using RT ± PCR, a signi®cant reduction in WT1 mRNA expression was detected in the PAX2 mutant glands compared to wildtype counterparts and double-antibody immunohistochemistry detected the co-localization of PAX2 and WT1 in the nuclei of normal and cancerous breast cells. These data indicate a role for PAX2 (and possibly WT1) in the regulation of the progesterone response of the mature mammary gland. The potential contribution of PAX2 to breast tumor pathogenesis is discussed.
Introduction
Previously, we demonstrated that the WT1 Wilms' tumor suppressor gene was expressed in normal human breast tissue as well as in a high percentage of breast tumors (Silberstein et al., 1997) . The WT1 protein may act as an activator or suppressor of transcription and is known to regulate several mammotrophic growth factor pathways, including insulin-like growth factor, epidermal growth factor, and transforming growth factor beta (Dey et al., 1994; Drummond et al., 1992; Vicanek et al., 1997; Werner et al., 1993) . WT1 is also expressed in the kidney, where it is positively regulated by the paireddomain transcription factor PAX2 and is required for the metanephric mesenchyme to respond to signals inducing cell proliferation (Dehbi et al., 1996; Kreidberg et al., 1993) . During embryonic kidney development PAX2 expression is transient whereas persistent expression of the gene in Wilms' kidney tumors (Dressler and Douglass, 1992) , renal cell carcinoma (Gnarra and Dressler, 1995) , and polycystic kidneys (Ostrom et al., 2000) suggests multiple roles in maintaining the dedierentiated or proliferative state and preventing apoptosis of the renal epithelium. Deregulated expression of PAX2 can transform cells in vitro and promote tumor formation in nude mice, indicating a direct role for PAX2 in tumorigenesis (Maulbecker and Gruss, 1993; Stuart and Gruss, 1996) . PAX2 expression in the mammary gland and its potential relationship with WT1 in that tissue has not been previously investigated, in part due to the death of PAX2 mutant mice within the ®rst hours after birth. Here we report the unexpected expression of PAX2 in normal human breast tissue, as well as in a high percentage of breast tumors. To begin to understand a functional role, we have rescued the mammary anlagen from PAX2-null mouse embryos to wild-type host mammary glands and now report that PAX2 is necessary for progesterone-dependent growth of lateral ductal branches.
Results

Expression of PAX2 in the normal and cancerous human breast
The expression of PAX2 in the human breast was investigated by immunohistochemistry and in situ hybridization. Using a polyclonal anti-PAX2 antibody (Dressler and Douglass, 1992) , nuclear staining was detected in cells from the two primary developmental lineages comprising myoepithelial and luminal cells in alveolar ( Figure 1a ) as well as ductal (Figure 1b) elements of the tissue. These cells are arranged in two circular layers and form a tube-within-a-tube. The innermost cells line the lumen, forming the ductal or acinar tube proper, and give rise to secretory structures at pregnancy, while the myoepithelium forms the epithelial boundary with the stroma and is comprised of contractile cells that facilitate milk extrusion (Silberstein, 2001) .
The histiotype of certain PAX2 positive cells with large, oval nuclei and diuse chromatin (Figure 1b) was consistent with that of putative mammary stem cells (Smith and Medina, 1988; Stingl et al., 1998; Toker, 1967; Williams and Daniel, 1983) . PAX2 positive luminal cells with this nuclear morphology coexisted with cells not ®tting this histiotype ( Figure  1a ). The not-infrequent side-by-side arrangement of PAX2 positive and negative cells (Figure 1b , boxes) may have functional signi®cance as paracrine signaling is known to be important in progesterone-dependent lateral branching (Brisken et al., 1998 (Brisken et al., , 2000 . Myoepithelial cells also exhibited a mixed, PAX2 positive and negative staining pattern (Figure 1a ,b), with some myoepithelial cells having less immunoreactivity than adjacent luminal cells (Figure 1b) . The localization of PAX2 mRNA in mammary tissue was detected by in situ hybridization and re¯ected PAX2 immuno-staining. In the pictured section of a branched duct PAX2, for example, PAX2 mRNA was found throughout the structure, with possibly higher amounts in the tips of developing branches (Figure 1c) . No signal was seen with a sense probe (Figure 1c, inset) .
Once we established the expression of PAX2 in the normal breast, mammary tumors were examined. Carcinoma in situ is one of the earliest histologically identi®able stages in breast tumor progression, in which proliferating cells occlude the lumen of a duct (Figure 1d ). In this example, the tumor cell mass consists primarily of PAX2 positive cells. The pattern of PAX2 mRNA expression re¯ected the immunohistochemistry, with small groupings of cells exhibiting little or no PAX2 mRNA interspersed with cells expressing high levels (Figure 1d, inset ). An in®ltrating ductal carcinoma (Figure 1e ) consisted of at least two cell populations, one with large, anaplastic nuclei, the second with smaller nuclei that were also abnormal; both cell types were PAX2 negative. A nearby, possibly less advanced element of this tumor, contained a mixture of PAX2 negative and positive cells (inset Figure 1e) .
In a more comprehensive survey, mammary carcinomas from 38 patients were grouped based on whether specimens had high or low numbers of PAX2 positive epithelial cells (Table 1 ). All histopathological types and grades of tumor were represented, and patients ranged in age from 19 to 88 years. PAX2 positive tumors were observed in 53% of these cases, with ®ve tumors having more or less equally mixed populations of PAX2 negative and positive cells. No correlation was noted between PAX2 staining and ductal versus lobular tumors. Pathological grading and estrogen/progesterone receptor expression status was available for a subset of the tumors (Table 2) . Lower grade and steroid receptor positive tumors were roughly equally divided between PAX2 positive and negative tumors. High grade and receptor negative tumors were more likely to be PAX2 negative; 86% of Grade 3 tumors and 75% of receptor negative tumors were PAX2 negative. WT1 and PAX2 expression were strongly correlated; 72% of PAX2 positive tumors were WT1 positive, while 85% of WT1 negative tumors were also PAX2 negative. This study added 18 more cases to the patient population originally screened for WT1 expression (Silberstein et al., 1997) . All 18 cases showed some degree of WT1 staining, supporting recent ®ndings that a much higher percentage of breast tumors are WT1-positive than was originally reported (Loeb et al., 2001) .
Transplantation rescue and progesterone insensitivity of PAX2-null mammary glands
To investigate the function of PAX2 in the mammary gland, we utilized the PAX2 null allele generated by homologous recombination. Mice homozygous for the PAX2 null allele die post-natally due to exencephaly and renal insuciency (Torres et al., 1996) . PAX2 null mammary anlagen were therefore rescued by grafting into wild-type mammary fat pads in immune compromized mice. PAX2 null mammary outgrowths were then divided and re-transplanted into multiple hosts for detailed analysis. In order to investigate the eects of PAX2 ablation on mammary growth and gene expression, fragments of PAX2 null and homotypic wild-type mammary tissue were simultaneously transplanted into contralateral mammary glands of individual hosts. This bilateral transplant experimental design ensures that mutant and control tissues are exposed to identical endocrinological and physiological backgrounds. Transplants were allowed 12 weeks to establish and grow, after which animals were treated with progesterone and estrogen for 7 days prior to sacri®ce.
Progesterone, but not estrogen, stimulates the growth of the higher order, lateral branching that is commonly associated with pregnancy in the mouse (Atwood et al., 2000) . When PAX2 null mammary glands were stimulated with a mixture of progesterone Tissue that was excised from the vicinity of a tumor, contained normal-appearing structures and cells that exhibited ductal and lobular PAX2 staining patterns as in Figure 1a ,b. Tumors studied: n = 38; classes represented: 27 in®ltrating ductal carcinomas, seven in®ltrating lobular carcinomas, medullary, colloid and adenocarcinoma, one each, and one unclassi®ed and estrogen the loss of PAX2 function resulted in stunted to non-existent lateral branching and poor lobular development, evidenced by the open architecture of the mutant gland (Figure 2a ) compared to its wild-type counterpart (Figure 2b) . In contrast to eects on lateral branching and lobular development, growth of the primary ductal framework was unaected; mutant and wild-type ducts grew the full length and breadth of the fat mammary fat pad. This point was con®rmed by examination of transplants after 7 weeks, at which time it was noted that mutant and wild-type ducts had extended an identical distance from their origin and had similar numbers of end buds (ductal growth points) of normal histo-morphology (not shown).
Examination of aected glands under higher magni®cation revealed that duct tips in the mutant tissue had failed to branch into the fatty stroma (compare boxed zones in Figures 2c,d ). In addition, the larger ducts had numerous, compact outgrowths ( Figure 2c , large arrows) comprised of epithelial cells lining a lumen (Figure 2e ). While not overtly dysplastic, these structures were unusual. The tips of PAX2 null ducts failed to undergo normal branching development (compare Figure 2c and d, small arrows). This was con®rmed at the histological level, where extensive normal branching at duct termini (Figure 2g , top) contrasted with simpli®ed termini in the mutant tissue (Figure 2f ). The accretion of ®brous stroma around the mutant ducts and smaller branches was similar to that seen in the wild-type tissue. It should be noted that some normal-appearing lobules were found in mutant tissue, usually in the vicinity of the transplant origin. This probably re¯ects known regional dierences in ductal sensitivity to hormones, in which the most dierentiated ducts (in the vicinity of the nipple in intact glands) require the least complex mixture of hormonal and growth factor stimulation (unpublished observations and DuBois and Elias, 1984) . In a second host strain (Balb/c, nu/nu), the PAX2 null phenotype was sometimes less pronounced indicating that stromal and physiological background play a role.
PAX2 and WT1 expression are coordinated and co-localize in human mammary cells
The PAX2 null status of mammary tissue derived from a rescued anlage was con®rmed by RT ± PCR using RNA isolated from bilaterally transplanted mutant and wild-type mammary glands (Figure 3a) . Since mutant epithelium grew into wild-type stroma the absence of an ampli®cation product also means that the bulk of PAX2 mRNA is epithelial and not stromal in origin. In the PAX2 null glands, there was a signi®cant reduction in WT1 mRNA apparently con®rming the predicted positive regulatory relationship between the two genes ( Figure 3a) . PCR primers spanning the alternative splice site in the WT1 regulatory domain (exon 5) were used and demonstrated that expression of both the plus and minus exon 5 isoforms were aected by PAX2. Similar results were seen with primers spanning a splice donor site (KTS) in the DNA binding domain (data not shown). Starting RNA concentrations were approximately equivalent as indicated by b-actin expression (Figure 3c) .
The relationship between PAX2 and WT1 was further investigated by double-antibody immuno-¯uor-escence. In the normal duct, PAX2 and WT1 coexpression was detected in luminal and myoepithelial cells (Figure 3c,d) , and in tumors, the nuclei of numerous in®ltrating cells contained both proteins (Figure 3e,f) . As noted earlier (Table 2) , PAX2 and WT1 expression were correlated in a high percentage of breast tumors. While suggestive, this positive correlation does not comment on same-cell expression because for the tumor survey immunostaining for each protein was examined in separate tissue sections.
Discussion
A function for PAX2 in the mammary gland had not been surmised in the previous investigations of gene expression patterns or mutant analyses. The early death of PAX2 mutant mouse newborns precludes any phenotypic characterization of mammary development directly. Once expression of PAX2 in the normal human mammary gland and in a high proportion of human breast cancers had been established (Figure 1 , Table 1 ), we investigated the PAX2 mammary phenotype by grafting PAX2 null embryonic glands into normal hosts. Whereas PAX2 mutant mammary epithelium underwent normal ductal development, as indicated by elongation and branching that was comparable to the wild-type, the injection of progesterone with estrogen failed to stimulate typical secondary branching and lobular growth (Figure 2 ). The mutant phenotype is consistent with higher levels of PAX2 expression in and around the branch points ( Figure  1b) , and indicates an important function for PAX2 in ER, estrogen receptor; PR, progesterone receptor: 23 tumors were screened for estrogen and progesterone receptor status. Concordance of Grade 3 and receptor-negative status was 100% (®ve out of ®ve of the tumors that comprised an overlapping set, e.g. were scored for each condition.) c WT1 immuno-stained tumors. Tissue sections were cut from the same paran-embedded specimens that were used for the PAX2 study (Table 1) mediating the progesterone response in the mature mammary gland.
The inhibition of side branching in PAX2 mutant mammary glands was similar to that seen in mammary glands in which the progesterone receptor or wnt-4 had been genetically ablated (Brisken et al., 1998 (Brisken et al., , 2000 . Wnt-4 is a secreted glycoprotein that was recently shown to act under progesterone stimulation in a paracrine mode driving ductal cells into secretory dierentiation (Brisken et al., 1998 (Brisken et al., , 2000 . In the developing kidney, PAX2 appears to act upstream of wnt-4 and low levels of PAX2 can be detected in wnt-4 mutants, indicating a regulatory relationship (Dressler, 2002; Stark et al., 1994) . Alternative explanations for the mutant phenotype include possible eects on mammary stem cell survival and faulty induction of the progesterone receptor. In other developing systems the loss of PAX2 leads to stem cell death and subsequent agenesis of the developing tissue (Brunner et al., 1999; Ostrom et al., 2000; Porteous et al., 2000) . If some PAX2 positive ductal cells are undierentiated, secretory progenitors (Figure 1a) , their absence in the Figure 2 Eects of the PAX2 null mutation on mouse mammary ductal and lobular growth. Contralaterally transplanted mutant and wild-type glands were taken from a single, bilaterally transplanted RAG1 mouse that had been treated with progesterone and estrogen for 7 days prior to sacri®ce. Whole-mount images of PAX2 null (a) and wild-type (b) mammary glands. Lateral (secondary) branching and lobular growth was considerably reduced in the mutant gland. Note that both the mutant and wild-type primary ducts ®lled the available fat pad. The mutant gland exhibited regional variation in secondary growth with some lobular growth nearest the site of transplantation (left side of image out of the picture; the direction of growth is from left to right as pictured). (Bar=2.5 mm). Details of branching and lobular growth in mutant (c) and wild-type (d) glands. The in-®lling of available fatty stroma by lateral branches and lobules was attenuated in the mutant (boxes highlight reduced lateral in-®lling in similar spaces in the mutant versus the wild-type gland. The ends of mutant ducts exhibited truncated branching compared with equivalent wild-type structures (small arrows) and unusual, compact outgrowths appeared on mutant ducts (c, large arrows). (Bar=625 mm). Histomorphology of mutant (e, f) and wild-type (g) ducts. Mutant glands exhibited numerous compact outgrowths that arose from larger ducts (large arrows). The ends of wild-type ducts typically exhibit extensive tertiary branching (g, top half of image) that was absent in the mutant (f, small arrow). Stromal investment of mutant outgrowths (e, small arrow) compared to wild-type (g, small arrow). (Bar=200 mm) mutant could be expected to impede progesteronedependent development of lateral branching. If PAX2 is necessary for normal mammary tissue estrogen responsiveness, then it is also possible that the loss of PAX2 could result in a failure of estrogen to properly induce the progesterone receptor thereby accounting for the PAX2 null phenotype.
A role for PAX2 in the pathogenesis and possibly the ontogeny of breast cancer is also suggested by our studies. As seen in polycystic kidney disease, the persistent (deregulated) expression of PAX2 contributes to pathogenesis by the combined mechanisms of preventing dierentiation and interfering with apoptosis (Ostrom et al., 2000) . Apoptosis is an important aspect of breast cancer pathogenesis that presents a complex and somewhat counter-intuitive picture. The highest rates are seen in the most aggressive, highly proliferative tumors, which were mainly PAX2 negative, while lower grade tumors, which are frequently PAX2 positive (Table 2) , have relatively low rates (Lipponen, 1999) . If PAX2 does aect mammary apoptosis, its expression could contribute to the pathogenesis of some breast tumors by blocking apoptosis early in progression or, by its absence during later stages, it could favor the selection of apoptosisresistant cells (Zhang et al., 1998) . Thus, PAX2 expression in breast tumors may contribute not only to proliferation, but also to cell survival by preventing dierentiation and apoptosis. Given its persistent expression in a high percentage of tumors, a role for PAX2 in tumor resistance to certain chemotherapies that depend for their eect on the stimulation of apoptosis is certainly worth investigating.
The expression patterns of PAX2 and WT1 showed a high degree of coincidence in the normal mammary gland as well as in tumors, consistent with, but not proving, a regulatory relationship between the two genes. PAX2 expression was seen in a relatively high percentage of tumors (Table 1 ) and of these, over 70% also expressed WT1 (Table 2) . If these tumors represent clonal expansions of PAX2 or WT1-positive ductal cells, this would indicate the special vulnerability of these cells to transformation. PAX2 null glands showed a marked reduction of WT1 mRNA expression that is consistent with a relationship that was previously established in the kidney (Figure 3a) . Twoantibody immunostaining demonstrated co-localization of PAX2 and WT1 in the nuclei of luminal and myoepithelial cells of the normal duct as well as in cells of an in®ltrating breast tumor supporting a potential direct regulatory relationship between the two genes in the mammary gland (Figure 3b) . Alternatively, lower WT1 mRNA levels (Figure 3a ) could also be due to selective death of PAX2/WT1 double-positive cells, leaving only the WT1 single-positive cells remaining in the mutant gland.
The eect of progesterone on normal and neoplastic mammary epithelial cells is paradoxical. During pregnancy, for example, the hormone simultaneously stimulates cell proliferation and lobulo-alveolar dierentiation and, depending on dosage and cell type, it can either stimulate or inhibit mammary tumor cell proliferation. Recent models now suggest that progesterone modulates a switching mechanism(s) that acts, in part, through nuclear transcription factors to control the activity of key genes involved in breast cell fate (Lange et al., 1999) . While the elements of this system are coming into focus, the transcription factor(s) that mediate the switching are unknown. In light of its role in cell fate determination in other systems and its dramatic eect on progesterone responsiveness, we suggest that PAX2 is a candidate to modulate fate switching in progesterone-responsive mammary cells and thus merits further investigation.
Materials and methods
Human mammary tissue
Specimens of ®xed, sectioned breast tumors were provided by the University of Michigan Breast Cell/Tissue Bank, where histological grading and steroid hormone receptor status were determined. Additional specimens used for immunohistochemical or in situ hybridization analysis were obtained directly after surgical excision, transferred immediately to chilled (48C) 4% paraformaldehyde in phosphate-buered saline (PBS) and ®xed for 3 h. Histological and steroid receptor typing of some of these specimens was performed by Dr KR O'Keefe, Dominican Hospital, Santa Cruz, CA, USA. Pathological grading and steroid hormone receptor status were available only for a subset of samples.
Rescue and clonal expansion of PAX2-homozygous recessive (null) mouse mammary anlagen E17 embryos from PAX2 heterozygote crosses in mice were removed from the uterus and PAX2 homozygous recessive mutants identi®ed by the characteristic exencephaly of the hindbrain and con®rmed by genotyping (Torres et al., 1996) . Dead mutant and companion embryos were then¯own overnight in ice-cold DMEM from the Dressler laboratory to Santa Cruz. PAX2 null and wild-type mammary anlage were surgically removed from the embryos and, without culturing, transplanted contralaterally into the inguinal fat pads of immune-ablated, Balb/C nu/nu mice, whose endogenous mammary parenchyma had previously been surgically excised (Robinson et al., 2000) . To guarantee complete`clearing' of the host parenchyma, each of the excised fragments was stained and examined in whole-mount to ensure that it contained the host parenchyma in its entirety. To determine transplant success, anlage were given approximately 4 weeks to grow, after which fragments of each gland were removed without sacri®cing the host and examined in whole-mount. Three independent sets of mutant and control transplants were established, and one set was selected for clonal expansion by transplantation into RAG1 immune-ablated mice.
Induction of ductal side-branching and lobular development
Transplants were allowed to grow for at least 6 weeks. To stimulate branching and lobular development animals were then treated with estrogen and progesterone (5 mg Depoestradiol in cottonseed oil plus 5 mg Depo-provera; Pharmacia/Upjohn, Kalamazoo, MI, USA) for 7 days via a long-acting, subcutaneous injection. To investigate morphology, glands were stained with hematoxylin for whole-mount analysis (Silberstein and Daniel, 1982) , photographed, then sectioned at 7 mm and restained with hematoxylin and eosin.
Immunohistochemistry
Using standard procedures, formalin-®xed, paran-embedded tissue was sectioned at 7 mm, deparanized, and sections incubated with a rabbit anti-PAX2 polyclonal antibody (PRB-276P, Covance/BAbCo, Berkeley, CA, USA) at a 1 : 50 ± 75 dilution in PBS. WT1 single-antibody immunohistochemistry has been described (Silberstein et al., 1997) . A biotin ± avidin secondary antibody system (Vector Laboratories, Burlingame, CA, USA) was used to produce the brown detection product.
For double-antibody immunostaining, sections were incubated overnight in a mixture of the PAX2 polyclonal antibody and a WT1 monoclonal antibody, the latter at a 1 : 25 dilution (PharMingen, San Diego, CA, USA; clone 2C12). Fluorescein-conjugated avidin was used in conjunction with biotinylated goat anti-mouse secondary antibody to detect WT1. Vector red dye (Vector Labs, Burlingame, CA, USA) was used according to the manufacturer's protocol in conjunction with biotinylated goat-anti rabbit secondary antibody to detect PAX2. A Leitz Aristoplan microscope interfaced with a CCD-array camera was used to capturē uorescent images.
In situ hybridization
A detailed protocol for in situ hybridization to mammary tissue appears elsewhere (Silberstein et al., 1996) . Digoxigenin-labeled anti-sense and sense-strand riboprobes were generated from a 527-bp BamHI ± EcoRI fragment of cDNA PAX2 clone c31A (Dressler et al., 1990 ) using 10X NTP labeling mixture (Boehringer-Mannheim, Indianapolis, IN, USA).
RNA preparation and RT ± PCR analysis
The isolation of mammary gland RNA, reverse transcription, and PCR analysis was as described (Silberstein et al., 1997) . RNA amounts were estimated by spectrophotometry and concentrations were equalized by dilution before ampli®cation. PAX2 expression was analysed with primers designed to amplify mouse or human cDNA. To detect low message levels, nested primer sets were used in two rounds of ampli®cation. One-sixth (3 ml) of the puri®ed DNA/RNA volume was subjected to ®rst round PCR ampli®cation (948C for 1 min, 588C for 2 min and 728C for 3 min for 30 cycles) using Taq polymerase (Fisher Scienti®c) in a 20 ml reaction volume in a Perkin-Elmer model 9600 thermal cycler. For the second round, a 1 : 10 dilution of the ®rst-round reaction mixture was made in a fresh reaction mixture containing the second set of primers and ampli®ed for 30 cycles (948C for 1 min, 618C for 2 min and 728C for 4 min). Primers for the initial ampli®cation were: (forward) 5'-CGACAGAACCCGACTATGTTCG-3'; (reverse) 5'-TGAATCTCCAAGCCTCRTTGTAG-3'. The internal primers¯anked the exon 10 alternative splice site and were (forward): 5'-GACC/TGGTCGTGAC/TATGA/GCGA-3'; (reverse): 5'-TGTAC/TGGGTTGCCG/TGAGAACT-3'. For b-actin ampli®cation (948C for 1 min followed by 35 cycles of 948C, 558C and 728C for 1 min each concluding with a 10 min extension at 728C), primers were (forward): 5'-GCTGGTCGTCGACAACGGCT-3'; (reverse): 5'-ATGA-CCTGGCCGTCAGGC-3'.
